Skip to main content
SpringerLink
Log in

Increased Levels of Soluble Tumor Necrosis Factor Receptors in Atherosclerosis: No Clear Relationship with Levels of Tumor Necrosis Factor

  • Published:
Inflammation Aims and scope Submit manuscript

Abstract

Inflammatory mediators, such as tumor necrosis factor alpha (TNF), may be important in the pathogenesis of atherosclerosis. Interactions between TNF and its target cell(s) requires the presence of specific receptors on the latter. Plasma levels of the two soluble forms of these receptors (tumor necrosis factor receptors, (sTNFr)) and TNF itself were measured by ELISA in 20 patients with peripheral vascular disease (PVD), 20 survivors of a myocardial infarction, and 20 age and sex matched controls. Levels of the p55 variant of the sTNFr were unchanged but levels of the p75 variant were increased in both groups of patients (ANOVA both P < 0.01). TNF was also raised in both groups of patients (both P < 0.05) but levels did not correlate with either sTNFr. In atherosclerosis, increased levels of p75 sTNFr may be further evidence of inappropriate leukocyte activation but unlikely to modulate the effect of free plasma TNF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Jonasson, L., J. Holm, O. Skalli, G. Bondjers, and G. K. Hansson. 1986. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6:131–138.

    Google Scholar 

  2. Libby, P., and G. K. Hansson. 1991. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Investigation, 64:5–15.

    Google Scholar 

  3. Warner, S. J. C., and P. Libby. 1989. Human vascular smooth muscle cells: target for and source of tumour necrosis factor. J. Immunol. 142:100–109.

    Google Scholar 

  4. Langler, E. G., W. Fiers, and V. W. M. van Hinsberg. 1991. Effects of tumour necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. Arteriosclerosis. Thromb. 11:872–881.

    Google Scholar 

  5. Robaye, B., R. Mosselamns, W. Fiers, J. E. Dumont, and P. Galand. 1991. Tumour necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am. J. Pathol. 138:447–453.

    Google Scholar 

  6. Thornhill, M. H., S. M. Wellicome, D. L. Mahiouz, J. S. S. Lanchbury, U. Kyan-Aung, and D. O. Haskard. 1991. Tumour necrosis factor combines with IL-4 or IFN gamma to selectively enhance endothelial cell adhesiveness for T cells. J. Immunol. 146:592–598.

    Google Scholar 

  7. Tipping, P. G., and W. W. Hancock. 1994. Production of tumour necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am. J. Pathol. 142:1721–1782.

    Google Scholar 

  8. K. Vaddi, F. A. Nicolini, P. Mehta, and J. L. Mehta. 1994. Increased secretion of tumour necrosis factor alpha and interferon gamma by mononuclear leukocytes in patients with ischaemic heart disease. Circulation 90:694–699.

    Google Scholar 

  9. van der Poll, T., S. J. H. van Deventer, G. Pasterkamp, J. A. van Mourik, H. R. Buller, and J. W. ten Cate. 1992. Tumour necrosis factor induces von Willebrand factor release in healthy humans. Thromb. Haemostas. 67:623–626.

    Google Scholar 

  10. Rothe, J., G. Gehr, H., Loetscher, W., Lesslauer. 1992. Tumour necrosis factor receptors—structure and function. Immunol. Res. 11:81–90.

    Google Scholar 

  11. Bazzoni, F., and B. Beutler. 1996. The tumour necrosis factor ligand and receptor families. New Engl. J. Med. 334:1717–1725.

    Google Scholar 

  12. Scannell, G., K. Waxman, G. J. Kaml, G. Iolo, T. Gatanaga, R. Yamamoto, and G. A. Granger. 1993. Hypoxia induces a human macrophage cell line to release tumour necrosis factor alpha and its soluble receptors in vitro. J. Surg. Res. 54:281–285.

    Google Scholar 

  13. Cope, A. P., D. Aderka, D. Wallach, M. Kahan, N. R. Chu, F. M. Brennan, and M. Feldmann. 1995. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 84:21–30.

    Google Scholar 

  14. Aderka, D., A. Wysenbeek, H. Englemann, A. P. Cope, F. Brennan, Y. Molad, V. Hornik, Y. Levo, R. M. Maini, M. Feldmann, and D. Wallach. 1993. Correlation between serum levels of soluble tumour necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 6:1111–1120.

    Google Scholar 

  15. Langkopf, F., and J. Atzpodien. 1994. Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet 344:57–58.

    Google Scholar 

  16. Englemann, H., D. Aderka, M. Rubenstein, D. Rotman, and D. Wallach. 1989. A tumour necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumour necrosis factor toxicity. J. Biol. Chem. 264:11966–11973.

    Google Scholar 

  17. Tannenbaum, S. H., and H. R. Gralnick. 1990. Gamma interferon modulates von Willebrand factor release by cultured human endothelial cells. Blood 75:2177–2184.

    Google Scholar 

  18. Lip, G. Y. H., and A. D. Blann. 1997. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res. 34:255–265.

    Google Scholar 

  19. Pottinger, B. E., R. C. Read, E. M. Paleolog, P. G. Higgins, and J. D. Pearson. 1989. Von Willebrand factor is an acute phase reactant in man. Thromb. Res. 53:387–394.

    Google Scholar 

  20. World Medical Association Declaration of Helsinki. 1997. Cardiovasc. Res. 35:2–3.

    Google Scholar 

  21. Short, P. E., C. E. Williams, A. M. Picken, and F. G. H. Hill. 1982. Factor VIII related antigen: an improved immunoassay. Med. Lab. Sci. 39:351–355.

    Google Scholar 

  22. Altman, D. G. In: Practical Statistics for Medical Research. Chapman and Hall, London, 1991, 455–460.

    Google Scholar 

  23. Lantz, M., S. Malik, M. L. Slevin, and I. Olsson. 1992. Infusion of tumour necrosis factor causes an increase in circulating TNF-binding protein in humans. Cytokines 2:402–406.

    Google Scholar 

  24. Boehme, M. W. J., R. Waldherr, A. Kist, S. Riedl, R. Walter-Kirst, J. Kempeni, and U. Raeth. 1996. Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin and VCAM-1 under systemic rhTNF-alpha therapy. Eur. J. Clin. Invest. 26:404–410.

    Google Scholar 

  25. Paleolog, E. M., M. A. Carew, and J. D. Pearson. 1991. Effects of tumour necrosis factor and interleukin-1 on von Willebrand factor secretion from human vascular endothelial cells. Int. J. Radiat. Biol. 60:279–285.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, The City Hospital, Dudley Road, Birmingham, B18 7QH, UK

    Andrew D. Blann

  2. University Department of Surgery, South Manchester University Hospital, Nell Lane, Didsbury, Manchester, M20 8LR, UK

    Charles N. McCollum

Authors
  1. Andrew D. Blann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles N. McCollum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blann, A.D., McCollum, C.N. Increased Levels of Soluble Tumor Necrosis Factor Receptors in Atherosclerosis: No Clear Relationship with Levels of Tumor Necrosis Factor. Inflammation 22, 483–491 (1998). https://doi.org/10.1023/A:1022346010304

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022346010304

Keywords

Search

Navigation